Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221972 | 0.94 | HMGCR (0.66) | HMGCR | |
| SCHEMBL6409537 | 0.94 | HMGCR (0.75) | HMGCR | |
| SCHEMBL5220259 | 0.94 | HMGCR (0.75) | HMGCR | |
| SCHEMBL5990992 | 0.92 | HMGCR (0.58) | HMGCR | |
| SCHEMBL5343613 | 0.91 | HMGCR (0.63) | HMGCR | |
| SCHEMBL5225435 | 0.91 | HMGCR (0.61) | HMGCR | |
| SCHEMBL5224857 | 0.91 | HMGCR (0.67) | HMGCR | |
| SCHEMBL5221964 | 0.91 | HMGCR (0.62) | HMGCR | |
| SCHEMBL5225557 | 0.90 | HMGCR (0.61) | HMGCR | |
| SCHEMBL5493958 | 0.89 | HMGCR (0.68) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007107843-A1 | METHODS OF TREATMENT WITH CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-09-27 | — | — | WO | claimed |
| EP-1994015-B1 | DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8383660-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-7919506-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100267765-A1 | Pharmaceutical Compositions and Methods for CCR5 Antagonists | FELSTEAD STEPHEN JOHN | 2010-10-21 | — | — | US | disclosed |
| EP-2120928-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR CCR5 ANTAGONISTS | Pfizer Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009027785-A2 | 1, 3-OXAZOLE DERIVATIVES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-1996564-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | Pfizer Products Incorporated (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1994015-A1 | DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS | Pfizer Products Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008099278-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR CCR5 ANTAGONISTS | PFIZER LIMITED (GN) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008038098-A1 | CRYSTALLINE FORM OF 7 [5-CYCLOPROPYL)-4-O-FLUOROBENZYLCARBAMOYL)-2-(4-FLUOROPHENYL)-IMIDAZOL-1-YL]-3R,5R-DIHYDROXYHEPTANOIC | PFIZER PRODUCTS INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007107843-A1 | METHODS OF TREATMENT WITH CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007105050-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007105049-A1 | DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213314-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
| EP-1740549-A2 | NOVEL IMIDAZOLES | Warner-Lambert Company LLC (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060287378-A1 | Novel pyrroles and imidazoles | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| WO-2005105079-A2 | NOVEL IMIDAZOLES | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050239857-A1 | Novel imidazoles | BOLTON GARY L | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213314-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | HMGCR 30/4885 |
| US-20060287378-A1 | Novel pyrroles and imidazoles | PPIP5K2, PPIE, PPOX | HMGCR 3534/4885 |
| US-20050239857-A1 | Novel imidazoles | HMGCR, HMGB2, HMGB3 | HMGCR 1/4885 |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | HMGCR 30/4885 |
| US-20100267765-A1 | Pharmaceutical Compositions and Methods for CCR5 Antagonists | CETP, CCR5, MTTP | HMGCR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.